The company said it had initiated the Phase III study of Olumiant, one of multiple JAK inhibitors that are being tested to find if they can mitigate the cytokine storm associated with Covid-19's worst complications. MediCityNews
The company said it had initiated the Phase III study of Olumiant, one of multiple JAK inhibitors that are being tested to find if they can mitigate the cytokine storm associated with Covid-19's worst complications. MediCityNews
No comments:
Post a Comment